Bausch + Lomb Corp.
BLCO
17.34
+0.16
+0.93%
Bausch + Lomb Corp.
US · BLCO
#1909 by market cap
Listed 2022
17.34
+0.16
+0.93%
Live - 5344 symbols - heartbeat 312s ago
· 2026-10-07 19:54
After-hours
17.34
0.00%
- Market cap
- 6.19B
- P/E (TTM)i
- -36.13
- P/Bi
- 0.97
- EPSi
- -1.02
- Div yieldi
- 0.00%
- 52W posi
- 65%
Reader sentiment
Are you bullish or bearish on BLCO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.1 percentage points.
Institutional ownership
- Held by institutions
- 97.37% -2.08pp
- Institutions
- 110 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Public Company88.32%
Hedge Fund4.72%
Mutual Fund1.74%
Family Office/Trust1.23%
VC/PE Fund1.12%
Individual/Insider0.33%
Private Company0.22%
Other2.30%
Top holders as of 2025-12-09
Bausch Health Companies Inc.
86.92% · 310.45M sh
Icahn Capital LP
0.98% · 3.50M sh
Brookfield Corporation
0.96% · 3.44M sh
Deutsche Bank Aktiengesellschaft
0.96% · 3.42M sh
D. E. Shaw & Co., L.P.
0.93% · 3.32M sh
Davidson Kempner Capital Management LP
0.88% · 3.16M sh
GoldenTree Asset Management LP
0.74% · 2.66M sh
T. Rowe Price Group, Inc.
0.61% · 2.16M sh
Glenview Capital Management, LLC
0.54% · 1.92M sh
Arrowstreet Capital, Limited Partnership
0.38% · 1.36M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| Bausch Health Companies Inc. | -- | 86.92% |
| Brenton Saunders | Chairperson & CEO | 0.12% |
| Osama Eldessouky | Chief Financial Officer | 0.06% |
| Yehia Hashad | Executive VP of Research & Development and Chief Medical officer | 0.05% |
| A. Robert Bailey | Chief Legal Officer | 0.04% |
| Andrew von Eschenbach | Independent Director | 0.01% |
| Luc Bonnefoy | President of Surgical | 0.01% |
| Richard De Schutter | Independent Director | 0.01% |
| Andrew Stewart | President of Global Pharmaceuticals & International Consumer | 0.01% |
| Thomas Appio | Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-27 | Karen Ling | Director | Intent to Sell (Form 144) | -4,500 | $16.83 |
| 2026-08-11 | Laurence Paul | Director | Other Acquisition | +11,776 | -- |
| 2026-08-11 | Robert Chersi | Director | Other Acquisition | +11,776 | -- |
| 2026-08-11 | Barbara Trebbi | Director | Other Acquisition | +11,776 | -- |
| 2026-08-09 | Frederick Munsch | Chief Accounting Officer | Open Market Disposition | -52,900 | $16.78 |
| 2026-08-09 | Frederick Munsch | Chief Accounting Officer | Intent to Sell (Form 144) | -52,900 | $16.78 |
| 2026-08-06 | Andrew von Eschenbach | Independent Director | Open Market Disposition | -18,559 | $16.50–16.58 |
| 2026-08-06 | Andrew von Eschenbach | Independent Director | Intent to Sell (Form 144) | -6,059 | $16.58 |
| 2026-08-05 | Andrew von Eschenbach | Independent Director | Intent to Sell (Form 144) | -12,500 | $16.50 |
| 2026-08-04 | Brenton Saunders | Chairperson & CEO | Sale to Issuer | -4,231 | $16.76 |
| 2026-08-04 | Brenton Saunders | Chairperson & CEO | Other Acquisition | +281,879 | -- |
| 2026-08-04 | Thomas Appio | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-04 | A. Robert Bailey | Chief Legal Officer | Other Acquisition | +33,557 | -- |
| 2026-08-04 | Osama Eldessouky | Chief Financial Officer | Other Acquisition | +50,335 | -- |
| 2026-08-04 | Yehia Hashad | Executive VP of Research & Development and Chief Medical officer | Other Acquisition | +20,973 | -- |
| 2026-08-04 | Frederick Munsch | Chief Accounting Officer | Other Acquisition | +9,091 | -- |
| 2026-08-04 | Andrew Stewart | President of Global Pharmaceuticals & International Consumer | Other Acquisition | +16,778 | -- |
| 2026-08-04 | Luc Bonnefoy | President of Surgical | Other Acquisition | +16,778 | -- |
| 2026-06-11 | Luc Bonnefoy | President of Surgical | Sale to Issuer | -1,008 | $15.08 |
| 2026-05-25 | Steven Collis | Director | Other Acquisition | +15,842 | $15.78 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.